Sidestepping Gene Therapy ‘Land Grab’ Mistakes, Rocket Is Set For First Filings In 2023
Two Rare Disease Filings Expected This Year
Executive Summary
While other gene therapy companies faced major clinical and financing problems in 2022, Rocket Pharma sidestepped some of these pitfalls and is gearing up for two US filings this year.
You may also be interested in...
Continuity Or Change? Roche’s New CEO And Pharma Leader Take On Big Strategy Question
Roche will suffer a hangover from its COVID-19 successes this year as revenues stagnate and its future strategy is yet to be laid out by incoming CEO Thomas Schinecker.
GSK Exceeded Expectations In 2022, Now Looking For Edge Over Pfizer In RSV Battle
Having outperformed in 2022, GSK is gearing up for key regulatory and market access decisions on its RSV vaccine, but is confident it holds superior data compared with rival Pfizer.
European Pharma 2023: A Rocky Year For Roche But Novo Is Rising Fast
Roche remains the European sector’s biggest company despite a wobble in 2022, but Novo Nordisk’s spectacular growth has seen it overtake AstraZeneca and Novartis in market cap terms.